Ceftizoxime


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : IV/IM Susceptible infections 1-2 g 8-12 hrly. Max: 2 g 4 hrly. Uncomplicated UTI 0.5 g 12 hrly. IM Uncomplicated gonorrhoea 1 g as a single dose.
Dosage Details
Intramuscular
Uncomplicated gonorrhoea
Adult: 1 g as a single dose.

Parenteral
Uncomplicated urinary tract infections
Adult: 0.5 g 12 hrly given as deep IM or slow IV inj over 3-5 min.

Parenteral
Susceptible infections
Adult: 1-2 g 8-12 hrly given as deep IM or slow IV inj over 3-5 min, increased to 2-4 g IV 8 hrly in severe infections. Max: 2 g 4 hrly.
Child: ≥6 mth 50 mg/kg 6-8 hrly.
Renal Impairment
Loading dose: 0.5-1 g. Maintenance: According to CrCl and severity of infection.
CrCl Dosage
<5 0.25-0.5 g 24 hrly or 0.5-1 g 48 hrly, after dialysis.
5-49 0.25-1 g 12 hrly.
50-79 0.5-1.5 g 8 hrly.
Contraindications
Hypersensitivity to ceftizoxime.
Special Precautions
Patient w/ history of GI disease, particularly colitis; hypersensitivity to penicillins. Renal impairment. Pregnancy and lactation.
Adverse Reactions
Rash, pruritus, fever; transient elevation in AST, ALT and alkaline phosphatase; transient eosinophilia, thrombocytosis; burning, cellulitis, phlebitis, pain, induration and tenderness at inj site, paraesthesia; nausea, vomiting, diarrhoea; transient rise in BUN and creatinine. Rarely, anaemia, neutropenia, leucopenia, thrombocytopenia, vaginitis, numbness.
Potentially Fatal: Anaphylaxis, pseudomembranous colitis.
IM/IV/Parenteral: B
MonitoringParameters
Carefully monitor renal function.
Drug Interactions
Renal clearance reduced w/ probenecid.
Lab Interference
May develop positive Coomb's test.
Action
Description: Ceftizoxime binds to 1 or more of the penicillin-binding proteins (PBPs) which inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
Pharmacokinetics:
Absorption: Time to peak plasma concentration: 1 hr.
Distribution: Widely distributed in body tissues and fluids; occur in CSF (therapeutic concentrations) when meninges are inflamed. Crosses the placenta and enters breast milk (low concentrations). Plasma protein binding: 30%.
Excretion: Via urine as unchanged drug w/in 24 hr. Plasma half-life: Approx 1.7 hr.
Chemical Structure

Click on icon to see table/diagram/image
Storage
Store at -20°C.
MIMS Class
ATC Classification
J01DD07 - ceftizoxime ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by MIMS based on Ceftizoxime from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Unizox
  • Zoxim
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in